Sun Pharma wins Brazilian approval for semaglutide injections

Sun Pharmaceutical Industries has received approval from Brazil's health regulator, Anvisa, to manufacture and market semaglutide injections for adults with inadequately controlled type 2 diabetes ^[1]. The Mumbai-based company plans to launch the product within days through a partnership with Brazil's Hypera Pharma ^[1].

The product will be sold as a pre-filled, multi-dose injectable pen in two strengths — 2 mg/1.5 mL and 4 mg/3 mL — taken once a week ^[1]. This dosing and delivery format mirrors Ozempic, the branded semaglutide product approved in the United States for type 2 diabetes, though Sun Pharma's version is a separate, Brazil-market product tied to that country's regulatory approval ^[1].

According to IQVIA data cited by the company, Brazil's semaglutide injectable market was worth about $413 million for the 12 months ending in June 2026 ^[1]. Aalok Shanghvi, Sun Pharma's chief operating officer, said the approval "expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes" and reflects the company's manufacturing capabilities ^[1]. Digvijay Singh, the company's regional head for Brazil and Latin America, said the approval would strengthen Sun Pharma's diabetes portfolio in the country ^[1].

The approval follows semaglutide patent expiries that have opened the door to generic competition in several countries ^[1]. Anvisa has recently cleared multiple semaglutide products in Brazil, and Sandoz, working with Adalvo, has also won marketing authorization there for a semaglutide product called Owozy ^[1].

Why it matters for patients

This approval is specific to Brazil and does not change what is available in U.S. pharmacies today. Semaglutide sold in the United States as Ozempic, Wegovy, and Rybelsus remains under patent protection there, and no generic semaglutide product has been approved for the U.S. market according to the source material ^[1]. Readers should not expect this Brazilian launch to lower prices or add new options at U.S. pharmacies in the near term.

Still, the development is a signal worth tracking. It shows that patent expiries are letting multiple manufacturers — Sun Pharma and Sandoz among them — bring semaglutide injections to market in at least one country outside the United States ^[1]. For patients following news about when generic or lower-cost semaglutide might eventually reach the U.S., this Brazilian approval is part of a broader pattern of expanding manufacturer competition abroad, even though the timing and terms of any future U.S. entry are not addressed in these sources.

It's also worth noting the approval covers a formulation for type 2 diabetes, not the higher-dose formulations marketed for weight management under names like Wegovy. The source material does not say whether Sun Pharma's Brazilian product will be used or marketed for weight loss.

What happens next

Sun Pharma said it plans to launch the product in Brazil within "the next few days" of the July 30, 2026, approval date, through its partnership with Hypera Pharma ^[1]. No timeline for U.S. approval or U.S. market entry is mentioned in the available reporting, and it is not yet known whether or when generic semaglutide injections might become available to American patients. Readers interested in domestic pricing and access changes will need to watch for separate U.S. regulatory and patent developments, which are not covered in this reporting.